Overview

Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
Phase:
Phase 1
Details
Lead Sponsor:
Merrimack Pharmaceuticals
South Plains Oncology Consortium
Collaborator:
South Plains Oncology Consortium
Treatments:
Camptothecin
Cyclophosphamide
Irinotecan